Fentiazac is a thiazole-based nonsteroidal anti-inflammatory drug (NSAID) developed for use in joint and muscular pain.[1] Like most other NSAIDs, it acts through inhibition of prostaglandin synthesis, via non-selective inhibition of both COX-1 and COX-2. First described in 1974, it was synthesized using the Hantzsch thiazole synthesis.[2]
Clinical data | |
---|---|
Trade names | Norvedan |
AHFS/Drugs.com | International Drug Names |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.038.129 |
Chemical and physical data | |
Formula | C17H12ClNO2S |
Molar mass | 329.80 g·mol−1 |
3D model (JSmol) |
|
Melting point | 162–163 °C (324–325 °F) |
| |
| |
(what is this?) (verify) |
Fentiazac was marketed under the trade-name Norvedan (among others), but its market status is currently unknown and assumed to be discontinued.[3]